In a new exclusive report, Insights from Specialty Physicians on GLP-1RA Medications Off-Label Use, Cure unveils the results of a specialty physician survey that sheds light on their current prescribing experiences, the challenges they face, and their expectations for future clinical applications of these drugs.
In the last four decades, the discovery and development of glucagon-like peptide 1 receptor agonists (GLP- 1RAs) reshaped the landscape of diabetes and weight management. These groundbreaking medications, initially approved for patients with type 2 diabetes, are now revolutionizing chronic disease treatment through their metabolic, hormonal, and anti-inflammatory effects, becoming vital tools in addressing conditions like cardiovascular disease, non-alcoholic fatty liver disease, osteoarthritis, and more.